関連する実験動画
Updated: Jul 11, 2026

07:22
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
アテロゲン炎症の転写抑制:PPARdeltaによる調節
Chih-Hao Lee1, Ajay Chawla, Ned Urbiztondo
1Howard Hughes Medical Institute, Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.
まとめ
ペロキシソーム増殖器活性化受容体 (PPAR) デルタはガンマではなく,泡細胞の炎症を制御する. 泡細胞のPPARdeltaを削除することで,動脈硬化性損傷の領域が著しく減少し,治療目標として示唆されています.
科学分野:
- 心血管生物学 心血管生物学
- 動脈硬化症の分子メカニズム
- 炎症と免疫について
背景:
- 動脈硬化病変の形成は,脂質に負荷されたマクロファージ (泡状細胞) と慢性炎症を含む.
- ペロキシソーム増殖器活性化受容体 (PPAR) ガンマは,泡細胞における脂質代謝に影響を与えます.
- マクロファージの炎症における関連するPPARデルタ受容体の役割は不明でした.
研究 の 目的:
- 動脈硬化性病変内のマクロファージの炎症状態を調節するPPARdeltaの役割を調査する.
- PPARdeltaが動脈硬化性病変の進行に影響を与えるかどうかを判断する.
主な方法:
- 発泡細胞に特化したPPARdeltaの遺伝子消去を活用した.
- 炎症マーカーと動脈硬化性病変のサイズに対するPPARデルタ除去の影響を評価した.
- PPARdelta. を含む転写制御メカニズムを調査しました.
主要な成果:
- 泡細胞におけるPPARdeltaの除去により,動脈硬化性病変の領域が著しく減少 (50%以上) しました.
- PPARデルタの削除は,マクロファージ内の炎症抑制剤の可用性を増加させた.
- PPARdeltaが転写抑制剤との相互作用を通じて炎症を調節するリガンド依存の転写経路を特定しました.
結論:
- PPAR gammaではなく,PPARdeltaは,動脈硬化症におけるマクロファージの炎症状態を制御する上で重要な役割を果たします.
- PPARdeltaとその結合体をターゲットにすることで,炎症を軽減し,動脈硬化症の進行を遅らせるための新しい治療戦略を提供することができます.
関連する概念動画
Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
